Edward Chung: Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends for Bio-Rad Laboratories, Inc. With me on the call today are ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

Bio-Rad Laboratories Inc. reports fourth-quarter results Thursday after market close, with investors looking to see whether the life sciences tools maker can sustain momentum from a strong prior ...

Bio-Rad develops products and solutions for the life sciences research and clinical diagnostic markets and enjoys niche market leadership in diagnostic quality controls, antigens, and digital ...

The collaborations will provide Illumina's customers with workflows for genomic disease characterization and spatial mapping.

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life ...

Albert Phung has 7+ years of experience as a process improvement consultant for several businesses; currently with Alberta Health Services. Dr. JeFreda R. Brown is a financial consultant, Certified ...